NEWS

19 August 2025

Akston Expands Leadership Team with Appointment of Two Veterinarians to Advance First-in-Class Biologics for Pets

18 February 2025

Akston Named Best Start-Up at the 2024 S&P Global Animal Health Awards

19 November 2024

Purdue University and Akston Biosciences Bring “First Dose of Hope” in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer

20 August 2024

Energesis and Akston Biosciences Sign Partnership Agreement for Companion Animal Obesity Drug Development

13 August 2024

Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development

30 July 2024

Dechra Purchases Veterinary Insulin Programs from Akston Biosciences

17 June 2024

Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors

13 March 2024

Animal health therapeutic development platform demonstrates versatility

10 March 2024

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect^® Platform’s Versatility

6 March 2024

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes

Press releases contained on the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date such press release was originally issued. This information may be out of date and Akston Biosciences Corporation has no obligation to update these materials.